28Feb 2015

RECK gene polymorphisms in hepatocellular carcinoma: association with susceptibility and clinicopathologic features in Egyptian patients

  • Abstract
  • Cite This Article as
  • Corresponding Author

Background The RECK (reversion-inducing cysteine rich protein with Kazal motifs) gene was initially isolated as a transformation suppressor gene. RECK down-regulation has been confirmed in numerous human cancers. The aim of this study was to investigate the association of RECK single-nucleotide polymorphisms (SNPs) with hepatocellular carcinoma (HCC) susceptibility and clinicopathologic characteristics in Egyptian patients. Methodology A total of 50 HCC cancer patients and 30 cancer-free controls were analyzed for RECK rs16932912 and rs11788747 genotyping using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Results RECK rs11788747 mutant genotypes AG/GG showed a 2.779 fold (95% CI: 1.091–7.080) higher risk of HCC compared to wild genotype (p=0.030) with a higher risk of lymph node metastasis (p = 0.034) and significantly higher levels of ALT, AST, and ALP (p=0.011, 0.001 and 0.003), respectively. RECK rs16932912 gene showed no statistical significance. Conclusions This study revealed the role of RECK rs11788747 polymorphism on HCC susceptibility and prognosis in Egyptian patients.


[Ayman Abdelsamie Gaber, Tarek Elsayed Darwish, Hanan Mohamed Farhan, Rania Elsayed Sheir (2015); RECK gene polymorphisms in hepatocellular carcinoma: association with susceptibility and clinicopathologic features in Egyptian patients Int. J. of Adv. Res. 3 (2). 0] (ISSN 2320-5407). www.journalijar.com


Dr Ayman Abdelsamie Gaber (Department of Oncology and Haematology, National Cancer Institute, Cairo University), Dr Tarek Elsayed Darwish (Department of Medical Oncology, National Cancer Institute, Cairo University), Dr Hanan Mohamed Farhan (Departme


Share this article